MetaADEDB 2.0 @ LMMD
Nafronyl
(KBAFPSLPKGSANY-UHFFFAOYSA-N)
Structure
SMILES
CCN(CCOC(=O)C(Cc1cccc2c1cccc2)CC1CCCO1)CC
Type(s)
Experimental
ATC code(s)
C04AX21
Molecular Formula:
C24H33NO3
Molecular Weight:
383.524
Log P:
4.4526
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
0
TPSA:
38.77
CAS Number(s):
31329-57-4
Synonym(s)
1.
Nafronyl
2.
Nafronyloxalate
3.
Naftidrofuryl
4.
Artocoron
5.
Azunaftil
6.
Di-Actane
7.
Dusodril
8.
Gévatran
9.
LS-121
10.
Nafronyl Oxalate
11.
Nafti Von Ct
12.
Nafti-Puren
13.
Nafti-Ratiopharm
14.
Naftifurin Oxalate
15.
Naftilong
16.
Naftilux
17.
Praxilene
18.
Praxilène
19.
Di Actane
20.
LS 121
21.
LS121
22.
Nafti Puren
23.
Nafti Ratiopharm
24.
NaftiRatiopharm
25.
Oxalate, Nafronyl
26.
Oxalate, Naftifurin
External Link(s)
MeSHD009257
PubChem Compound4417
BindingDB50347133
ChEBI91817
CHEMBLCHEMBL1620794
DrugBankDB13588
DrugCentral1870
KEGGdr:D08244
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AcidosisOFFSIDES
2Amnesia1763119CTD
3Antiviral drug level above therapeuticOFFSIDES
4ApathyOFFSIDES
5Atrial tachycardiaOFFSIDES
6AuraOFFSIDES
7BicytopeniaOFFSIDES
8Blood creatinine increasedOFFSIDES
9Blood lactate dehydrogenase increasedOFFSIDES
10Blood sodium increasedOFFSIDES
11Blood sodiumOFFSIDES
12Brain natriuretic peptide increasedOFFSIDES
13BronchiolitisOFFSIDES
14Cardio-respiratory distressOFFSIDES
15Cardioactive drug level increasedOFFSIDES
16Cerebral atrophyOFFSIDES
17Chemotherapeutic drug level increasedOFFSIDES
18CholangiolitisOFFSIDES
19Circumstance or information capable of leading to medication errorOFFSIDES
20Clostridium difficile colitisOFFSIDES
21ConfabulationOFFSIDES
22Creatinine renal clearance decreasedOFFSIDES
23Cytolytic hepatitisOFFSIDES
24DehydrationOFFSIDES
25Dementia19672037CTD
26DrowsinessOFFSIDES
27Drug administration errorOFFSIDES
28Drug dispensing errorOFFSIDES
29Drug resistanceOFFSIDES
30Duodenal ulcer perforationOFFSIDES
31EczemaOFFSIDES
32Ejection Fraction DecreasedOFFSIDES
33EnterocolitisOFFSIDES
34Febrile infectionOFFSIDES
35Gastrointestinal motility disorderOFFSIDES
36Gastrointestinal ulcer perforationOFFSIDES
37General physical health deteriorationOFFSIDES
38GranulocytosisOFFSIDES
39HepatitisOFFSIDES
40Hepatojugular refluxOFFSIDES
41Infrequent bowel movementsOFFSIDES
42Intention tremorOFFSIDES
43Intentional misuseOFFSIDES
44Intermittent Claudication19672037CTD
45Kidney FailureOFFSIDES
46Large intestine perforationOFFSIDES
47LeukoencephalopathyOFFSIDES
48Memory Disorders10091712CTD
49Metabolic acidosisOFFSIDES
50Motor retardationOFFSIDES
51Multiple drug overdoseOFFSIDES
52OverdoseOFFSIDES
53Personality ChangeOFFSIDES
54PhlebitisOFFSIDES
55PneumoperitoneumOFFSIDES
56PolymyositisOFFSIDES
57Potentiating drug interactionOFFSIDES
58ProctitisOFFSIDES
59PyelonephritisOFFSIDES
60Status EpilepticusOFFSIDES
61Stent occlusionOFFSIDES
62SubileusOFFSIDES
63Superficial ThrombophlebitisOFFSIDES
64Thrombosis in deviceOFFSIDES
65Transmission of an infectious agent via a medicinal productOFFSIDES
66Vaginal ProlapseOFFSIDES
67diagnostic procedureOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.